A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial
2015 ◽
Vol 21
(11)
◽
pp. 1907-1913
◽
Keyword(s):
Phase Ii
◽
2020 ◽
Vol 26
(3)
◽
pp. S188
2015 ◽
Vol 21
(5)
◽
pp. 906-912
◽
2003 ◽
Vol 9
(11)
◽
pp. 714-721
◽
Keyword(s):